Recently, we reported that the modulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated cytotoxic pathway could partially contribute to the anti-HCC effect of IFN-α/5-FU combination therapy (Yamamoto et al, 2004). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.